Treats acne vulgaris. Sold as Aklief. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Trifarotene (sold as Aklief), first approved Oct 4, 2019, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Aklief | Part D | $303K | +17% | 217 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne VulgarisAcne Vulgaris · Galderma R&D | Phase 3 | Active, not recruiting | Sep 22, 2025 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Oct 4, 2019 | AkliefNDA 211527 · New molecular entity | Galderma Labs LP | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
